RLAY stock forecast, quote, news & analysis
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients... Show more
Relay Therapeutics (RLAY) Stock Analysis: Clinical Pipeline Momentum Offsets Dilution Concerns
Key Takeaways
- Relay Therapeutics shares have traded in a range of approximately $18.44 to $20.79 over the past 30 days, reflecting consolidation after a powerful multi-month rally.
- The stock surged roughly 48% over the last quarter, driven by positive clinical data across the zovegalisib program in breast cancer and vascular anomalies.
- A $275 million public offering in May 2026 temporarily pressured shares, but strong institutional demand and bullish analyst coverage absorbed the dilution.
- Wall Street analysts maintain a consensus "Buy" rating with an average price target of approximately $24, implying further upside from current levels.
- Insider selling by the CEO, CFO, and other executives has been notable in recent weeks, introducing a layer of caution for some investors.
- Key upcoming catalysts include additional zovegalisib data readouts, the frontline Phase 3 trial launch in early 2027, and initial clinical data from the NRAS-selective inhibitor RLY-8161.
Current Market Snapshot
Relay Therapeutics (RLAY) has entered a period of consolidation after a sharp rally that propelled shares from the low teens to above $20 in a matter of months. The stock reached a 52-week high of $20.79 in early July 2026 before settling into the $18–$19 range, where it currently trades. With a market capitalization of approximately $3.7 billion and institutional ownership near 97%, RLAY remains heavily anchored by professional investors who appear focused on the long-term clinical narrative rather than near-term volatility. The 50-day moving average sits near $15.81, well below the current share price, while the 200-day moving average at approximately $12.27 underscores the magnitude of the stock's upward trajectory over the past year.
Relay Therapeutics (RLAY) Business Overview and Competitive Position
Relay Therapeutics is a clinical-stage precision medicine company headquartered in Cambridge, Massachusetts, founded in 2016 with a differentiated approach to drug discovery. The company's proprietary Dynamo® platform integrates computational modeling, molecular dynamics simulations, cryo-electron microscopy, and biophysical screening to drug protein targets that have historically been considered intractable. Its lead asset, zovegalisib (RLY-2608), is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 registrational trial (ReDiscover-2) for HR+/HER2- metastatic breast cancer. Zovegalisib is also under investigation for PIK3CA-driven vascular anomalies, a rare-disease indication with significant unmet need. The pipeline further includes RLY-8161, an NRAS-selective inhibitor in Phase 1/2 for NRAS-mutant solid tumors, and a preclinical program for Fabry disease. Relay's partnership with Pfizer (PFE), which will supply atirmociclib and palbociclib for the planned frontline breast cancer trial, adds strategic validation.
Recent Developments Driving RLAY
The most significant recent catalyst for Relay Therapeutics was the vascular anomalies data presentation at the ISSVA World Congress in May 2026, which demonstrated zovegalisib's potential in a second major indication beyond oncology. Combined with the FDA's Breakthrough Therapy designation for zovegalisib in PIK3CA-mutant, HR+/HER2- advanced breast cancer, the clinical narrative has strengthened considerably. The company also presented compelling triplet combination data showing a 44% objective response rate in heavily pre-treated breast cancer patients using zovegalisib plus atirmociclib. On the capital markets front, Relay priced a $275 million public offering at $12.00 per share in May — a dilutive event that initially pressured shares but was subsequently absorbed as clinical momentum outweighed financing concerns. The company ended Q1 2026 with approximately $642 million in cash, providing runway into 2029. More recently, Canaccord Genuity upgraded RLAY to "Strong-Buy" in mid-July, while JPMorgan initiated coverage with an Overweight rating and a $28 price target. On the other side of the ledger, insider selling has been pronounced: CEO Sanjiv Patel sold approximately $944,000 worth of shares in early July, and CFO Thomas Catinazzo executed multiple sales over the past quarter, which some market participants view as a modest near-term headwind.
Trending AI Robots
For traders seeking a data-driven approach to navigating stocks like Relay Therapeutics, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron hosts hundreds of automated trading bots that collectively trade thousands of tickers across various strategies, timeframes, and risk profiles — but only the top-performing and most relevant bots are featured in this section. Each bot is designed with distinct algorithms tailored to specific market conditions, from momentum-based swing trading to longer-term trend-following approaches. Whether tracking biotech breakouts or managing risk in volatile sectors, these AI tools provide traders with systematic, emotion-free decision-making frameworks. Exploring the Trending AI Robots page can help investors identify strategies aligned with their own objectives and market outlook.
2026 Outlook and What Investors Should Watch
Looking ahead, Relay Therapeutics is positioned for a data-rich second half of 2026 and early 2027. The Phase 3 ReDiscover-2 trial for zovegalisib in second-line breast cancer remains the cornerstone of the investment thesis, with enrollment progressing and eventual topline results representing the most consequential binary event for the stock. The planned frontline Phase 3 study combining zovegalisib with atirmociclib, expected to launch in early 2027 with Pfizer as a clinical supply partner, could meaningfully expand the addressable patient population. Investors should also monitor initial clinical data from the Phase 1/2 trial of RLY-8161 in NRAS-mutant solid tumors, as this program represents Relay's next pipeline catalyst beyond zovegalisib. Macroeconomic factors, including interest rate policy and biotech sector fund flows, may influence risk appetite for pre-revenue clinical-stage names. The company's strong cash position provides a buffer, but the pace of insider selling warrants monitoring as an indicator of management sentiment. With a consensus analyst price target near $24 and a high institutional ownership base, the stock's trajectory will likely be dictated by clinical execution and data quality above all else.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Aroon Indicator for RLAY shows an upward move is likely
RLAY's Aroon Indicator triggered a bullish signal on July 20, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 217 similar instances where the Aroon Indicator showed a similar pattern. In of the 217 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 04, 2026. You may want to consider a long position or call options on RLAY as a result. In of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for RLAY just turned positive on August 12, 2026. Looking at past instances where RLAY's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RLAY advanced for three days, in of 273 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for RLAY moved out of overbought territory on July 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RLAY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RLAY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.909) is normal, around the industry mean (20.121). P/E Ratio (0.000) is within average values for comparable stocks, (25.620). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.855). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (357.143) is also within normal values, averaging (466.660).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RLAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage precision medicines company, which focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets
Industry Biotechnology